Purification of Cannabinoid Receptors Type 1 and 2

Information

  • Research Project
  • 6647525
  • ApplicationId
    6647525
  • Core Project Number
    R43DA016476
  • Full Project Number
    1R43DA016476-01
  • Serial Number
    16476
  • FOA Number
    PA-02-60
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 20 years ago
  • Project End Date
    7/31/2004 - 19 years ago
  • Program Officer Name
    LOGRASSO, PHILIP
  • Budget Start Date
    8/1/2003 - 20 years ago
  • Budget End Date
    7/31/2004 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/18/2003 - 20 years ago

Purification of Cannabinoid Receptors Type 1 and 2

DESCRIPTION (provided by applicant): Obtaining atomic resolution structures of membrane proteins such as G-protein coupled receptors (GPCRs) has been hampered by the difficulty to purify sufficient amounts of membrane protein. The only GPCR crystal structure available is bovine rhodopsin, which can be isolated in large amounts from bovine retina. We propose a novel approach to generate a source to purify large amounts of receptor, which could solve the bottleneck for GPCR crystallization. The covalently bound retinal of rhodopsin acts as an inverse agonist that maintains firmly the receptor in a very stable inactive state. Stability and homogeneity of the protein are key factors for the formation of highly ordered crystals that diffract at high resolution. The cannabinoid receptors (CBR) are the closest to rhodopsin in that when bound to the inverse agonist they exhibit a very stable inactive state, in this case associated with the G-protein, making them attractive GPCR targets for crystallization and structural elucidation. In Phase I we will test the feasibility of our novel source for receptor purification for CB1 and CB2 receptors, a prerequisite to a Phase II application for crystallization and structural elucidation of the CB1 and CB2 receptors, alone and complexed with G-protein in the inverse agonist bound state.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R43
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    250001
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:250001\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NOVASITE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    113386366
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES